IRMD

SEC source: 0000898432-21-000493 · form4.xml · nonDerivative · entry 2

Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,907

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021.

F3 · price: This transaction was executed in multiple trades at prices ranging from $27.50 to $28.38. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0000898432-21-000493 · form4.xml · nonDerivative · entry 1

Susi Roger E. · CIK 0001613801 · Director · President, CEO and Chairman · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,907

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021.

F2 · price: This transaction was executed in multiple trades at prices ranging from $28.40 to $28.70. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0000898432-20-001023 · form4.xml · nonDerivative · entry 1

VUOTO ANTHONY · CIK 0001222060 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,526

F1 · price: This transaction was executed in multiple trades at prices ranging from $24.51 to $24.75. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0000898432-20-001025 · form4.xml · derivative · entry 3

Scott Christopher K. · CIK 0001613803 · CFO & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,417 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: On December 14, 2016, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on December 14, 2017. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F2 · derivative.expiration_date: On December 14, 2016, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on December 14, 2017. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0000898432-20-001025 · form4.xml · nonDerivative · entry 1

Scott Christopher K. · CIK 0001613803 · CFO & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,939

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

SEC source: 0000898432-20-000868 · form4.xml · derivative · entry 3

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,185

Underlying: Common Stock · 2,185 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F4 · derivative.exercise_date: On December 7, 2019, The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2020. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F4 · derivative.expiration_date: On December 7, 2019, The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2020. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0000898432-20-000868 · form4.xml · derivative · entry 2

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,370

Underlying: Common Stock · 4,370 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Iradimed Corporation's common stock.

F3 · derivative.exercise_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2021. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F3 · derivative.expiration_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2021. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0000898432-20-000868 · form4.xml · nonDerivative · entry 1

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

SEC source: 0000898432-20-000871 · form4.xml · derivative · entry 8

Scott Christopher K. · CIK 0001613803 · CFO & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,195

Underlying: Common Stock · 2,731 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F6 · derivative.exercise_date: On December 7, 2019, The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on December 7, 2020. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F6 · derivative.expiration_date: On December 7, 2019, The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on December 7, 2020. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0000898432-20-000871 · form4.xml · derivative · entry 7

Scott Christopher K. · CIK 0001613803 · CFO & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,150

Underlying: Common Stock · 1,575 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F5 · derivative.exercise_date: On December 7, 2018, The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on December 7, 2019. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F5 · derivative.expiration_date: On December 7, 2018, The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on December 7, 2019. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0000898432-20-000871 · form4.xml · derivative · entry 6

Scott Christopher K. · CIK 0001613803 · CFO & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,093

Underlying: Common Stock · 5,093 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Iradimed Corporation's common stock.

F4 · derivative.exercise_date: The reporting person received performance-based restricted stock units ("PRSUs") under Iradimed Corporation's 2014 Equity Incentive Plan. Vesting of these PRSUs depends on the reporting person's achievement of a specified relative ranking of total stockholder return over a three-year period from December 8, 2020 through December 7, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of PRSUs that have vested.

F4 · derivative.expiration_date: The reporting person received performance-based restricted stock units ("PRSUs") under Iradimed Corporation's 2014 Equity Incentive Plan. Vesting of these PRSUs depends on the reporting person's achievement of a specified relative ranking of total stockholder return over a three-year period from December 8, 2020 through December 7, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of PRSUs that have vested.

SEC source: 0000898432-20-000871 · form4.xml · derivative · entry 5

Scott Christopher K. · CIK 0001613803 · CFO & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,094

Underlying: Common Stock · 5,094 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Iradimed Corporation's common stock.

F3 · derivative.exercise_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in full on the third anniversary of the grant date, December 7, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F3 · derivative.expiration_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in full on the third anniversary of the grant date, December 7, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0000898432-20-000871 · form4.xml · nonDerivative · entry 3

Scott Christopher K. · CIK 0001613803 · CFO & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,187

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

SEC source: 0000898432-20-000871 · form4.xml · nonDerivative · entry 1

Scott Christopher K. · CIK 0001613803 · CFO & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,840

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

SEC source: 0000898432-20-000869 · form4.xml · derivative · entry 5

ALLEN MONTY K · CIK 0001253352 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,185

Underlying: Common Stock · 2,185 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F5 · derivative.exercise_date: On December 7, 2019, The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2020. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F5 · derivative.expiration_date: On December 7, 2019, The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2020. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0000898432-20-000869 · form4.xml · derivative · entry 4

ALLEN MONTY K · CIK 0001253352 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,969 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F4 · derivative.exercise_date: On December 7, 2018, The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2019. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F4 · derivative.expiration_date: On December 7, 2018, The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2019. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0000898432-20-000869 · form4.xml · derivative · entry 3

ALLEN MONTY K · CIK 0001253352 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,074

Underlying: Common Stock · 4,074 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Iradimed Corporation's common stock.

F3 · derivative.exercise_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2021. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F3 · derivative.expiration_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2021. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0000898432-20-000869 · form4.xml · nonDerivative · entry 2

ALLEN MONTY K · CIK 0001253352 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,375

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

SEC source: 0000898432-20-000869 · form4.xml · nonDerivative · entry 1

ALLEN MONTY K · CIK 0001253352 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,190

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

SEC source: 0000898432-20-000867 · form4.xml · derivative · entry 5

VUOTO ANTHONY · CIK 0001222060 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,185

Underlying: Common Stock · 2,185 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F5 · derivative.exercise_date: On December 7, 2019, The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2020. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F5 · derivative.expiration_date: On December 7, 2019, The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2020. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0000898432-20-000867 · form4.xml · derivative · entry 4

VUOTO ANTHONY · CIK 0001222060 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,969 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F4 · derivative.exercise_date: On December 7, 2018, The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2019. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F4 · derivative.expiration_date: On December 7, 2018, The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2019. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0000898432-20-000867 · form4.xml · derivative · entry 3

VUOTO ANTHONY · CIK 0001222060 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,074

Underlying: Common Stock · 4,074 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Iradimed Corporation's common stock.

F3 · derivative.exercise_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2021. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F3 · derivative.expiration_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2021. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0000898432-20-000867 · form4.xml · nonDerivative · entry 2

VUOTO ANTHONY · CIK 0001222060 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,494

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

SEC source: 0000898432-20-000867 · form4.xml · nonDerivative · entry 1

VUOTO ANTHONY · CIK 0001222060 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,309

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

SEC source: 0000898432-21-000513 · form4.xml · derivative · entry 3

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,185

Underlying: Common Stock · 2,185 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert to common stock on a one-for-one basis.

F5 · derivative.exercise_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2020. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F5 · derivative.expiration_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2020. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0000898432-21-000513 · form4.xml · derivative · entry 2

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,074

Underlying: Common Stock · 4,074 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Iradimed Corporation's common stock.

F3 · shares: This amendment is being filed to correct the amount of restricted stock units previously reported on the reporting person's Form 4 filed on December 9, 2020. The amount previously reported was 4,370 and it should have been 4,074.

F4 · derivative.exercise_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2021. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F4 · derivative.expiration_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 7, 2021. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0000898432-21-000513 · form4.xml · nonDerivative · entry 1

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert to common stock on a one-for-one basis.

SEC source: 0000898432-20-000866 · form4.xml · derivative · entry 3

Scott Christopher K. · CIK 0001613803 · CFO and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,952

Underlying: Common Stock · 2,952 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: On December 4, 2017, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on December 4, 2018. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F2 · derivative.expiration_date: On December 4, 2017, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on December 4, 2018. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0000898432-20-000866 · form4.xml · nonDerivative · entry 2

Scott Christopher K. · CIK 0001613803 · CFO and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,265

SEC source: 0000898432-20-000866 · form4.xml · nonDerivative · entry 1

Scott Christopher K. · CIK 0001613803 · CFO and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,984

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

SEC source: 0000898432-20-000709 · form4.xml · nonDerivative · entry 1

ALLEN MONTY K · CIK 0001253352 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,221

F1 · price: This transaction was executed in multiple trades at prices ranging from $22.00 to $22.60. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0000898432-20-000690 · form4.xml · nonDerivative · entry 1

Susi Roger E. · CIK 0001613801 · Director · President, CEO, and Chairman · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Roger E. Susi Revocable Trust

Disclosed balance after: 985,050

F1 · balance_after: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000898432-20-000675 · form4.xml · derivative · entry 6

Waldman Louis S. · CIK 0001613666 · Former Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,748 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F1 · kind: As previously disclosed, the reporting person received restricted stock units under the Issuer's 2014 Equity Incentive Plan on December 14, 2016, December 4, 2017, December 7, 2018, and December 7, 2019. Pursuant to the reporting person's separation agreement with the Issuer (the "Separation Agreement"), upon his separation from the Issuer on July 24, 2020 (the "Retirement Date"), all of his unvested restricted stock units, amounting to 5,155 shares of common stock, accelerated and vested as of the Retirement Date as follows: (i) 750 unvested restricted stock units accelerated and vested from the December 14, 2016 grant; (ii) 1,476 unvested restricted stock units accelerated and vested from the December 4, 2017 grant; (iii) 1,181 unvested restricted stock units accelerated and vested from the December 7, 2018 grant; and (iv) 1,748 unvested restricted stock units accelerated and vested from the December 7, 2019 grant (collectively, the "RSUs").

F4 · derivative.exercise_date: All of the unvested RSUs were accelerated on the Retirement Date pursuant to the terms of the Separation Agreement.

F4 · derivative.expiration_date: All of the unvested RSUs were accelerated on the Retirement Date pursuant to the terms of the Separation Agreement.

SEC source: 0000898432-20-000675 · form4.xml · derivative · entry 5

Waldman Louis S. · CIK 0001613666 · Former Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,181 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F1 · kind: As previously disclosed, the reporting person received restricted stock units under the Issuer's 2014 Equity Incentive Plan on December 14, 2016, December 4, 2017, December 7, 2018, and December 7, 2019. Pursuant to the reporting person's separation agreement with the Issuer (the "Separation Agreement"), upon his separation from the Issuer on July 24, 2020 (the "Retirement Date"), all of his unvested restricted stock units, amounting to 5,155 shares of common stock, accelerated and vested as of the Retirement Date as follows: (i) 750 unvested restricted stock units accelerated and vested from the December 14, 2016 grant; (ii) 1,476 unvested restricted stock units accelerated and vested from the December 4, 2017 grant; (iii) 1,181 unvested restricted stock units accelerated and vested from the December 7, 2018 grant; and (iv) 1,748 unvested restricted stock units accelerated and vested from the December 7, 2019 grant (collectively, the "RSUs").

F4 · derivative.exercise_date: All of the unvested RSUs were accelerated on the Retirement Date pursuant to the terms of the Separation Agreement.

F4 · derivative.expiration_date: All of the unvested RSUs were accelerated on the Retirement Date pursuant to the terms of the Separation Agreement.

SEC source: 0000898432-20-000675 · form4.xml · derivative · entry 4

Waldman Louis S. · CIK 0001613666 · Former Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,476 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F1 · kind: As previously disclosed, the reporting person received restricted stock units under the Issuer's 2014 Equity Incentive Plan on December 14, 2016, December 4, 2017, December 7, 2018, and December 7, 2019. Pursuant to the reporting person's separation agreement with the Issuer (the "Separation Agreement"), upon his separation from the Issuer on July 24, 2020 (the "Retirement Date"), all of his unvested restricted stock units, amounting to 5,155 shares of common stock, accelerated and vested as of the Retirement Date as follows: (i) 750 unvested restricted stock units accelerated and vested from the December 14, 2016 grant; (ii) 1,476 unvested restricted stock units accelerated and vested from the December 4, 2017 grant; (iii) 1,181 unvested restricted stock units accelerated and vested from the December 7, 2018 grant; and (iv) 1,748 unvested restricted stock units accelerated and vested from the December 7, 2019 grant (collectively, the "RSUs").

F4 · derivative.exercise_date: All of the unvested RSUs were accelerated on the Retirement Date pursuant to the terms of the Separation Agreement.

F4 · derivative.expiration_date: All of the unvested RSUs were accelerated on the Retirement Date pursuant to the terms of the Separation Agreement.

SEC source: 0000898432-20-000675 · form4.xml · derivative · entry 3

Waldman Louis S. · CIK 0001613666 · Former Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 750 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F1 · kind: As previously disclosed, the reporting person received restricted stock units under the Issuer's 2014 Equity Incentive Plan on December 14, 2016, December 4, 2017, December 7, 2018, and December 7, 2019. Pursuant to the reporting person's separation agreement with the Issuer (the "Separation Agreement"), upon his separation from the Issuer on July 24, 2020 (the "Retirement Date"), all of his unvested restricted stock units, amounting to 5,155 shares of common stock, accelerated and vested as of the Retirement Date as follows: (i) 750 unvested restricted stock units accelerated and vested from the December 14, 2016 grant; (ii) 1,476 unvested restricted stock units accelerated and vested from the December 4, 2017 grant; (iii) 1,181 unvested restricted stock units accelerated and vested from the December 7, 2018 grant; and (iv) 1,748 unvested restricted stock units accelerated and vested from the December 7, 2019 grant (collectively, the "RSUs").

F4 · derivative.exercise_date: All of the unvested RSUs were accelerated on the Retirement Date pursuant to the terms of the Separation Agreement.

F4 · derivative.expiration_date: All of the unvested RSUs were accelerated on the Retirement Date pursuant to the terms of the Separation Agreement.

SEC source: 0000898432-20-000675 · form4.xml · nonDerivative · entry 2

Waldman Louis S. · CIK 0001613666 · Former Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,901

F2 · shares: Shares surrendered to the Issuer for payment of tax liability incident to the accelerated vesting of a total of 5,155 restricted stock units.

SEC source: 0000898432-20-000675 · form4.xml · nonDerivative · entry 1

Waldman Louis S. · CIK 0001613666 · Former Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,155

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: As previously disclosed, the reporting person received restricted stock units under the Issuer's 2014 Equity Incentive Plan on December 14, 2016, December 4, 2017, December 7, 2018, and December 7, 2019. Pursuant to the reporting person's separation agreement with the Issuer (the "Separation Agreement"), upon his separation from the Issuer on July 24, 2020 (the "Retirement Date"), all of his unvested restricted stock units, amounting to 5,155 shares of common stock, accelerated and vested as of the Retirement Date as follows: (i) 750 unvested restricted stock units accelerated and vested from the December 14, 2016 grant; (ii) 1,476 unvested restricted stock units accelerated and vested from the December 4, 2017 grant; (iii) 1,181 unvested restricted stock units accelerated and vested from the December 7, 2018 grant; and (iv) 1,748 unvested restricted stock units accelerated and vested from the December 7, 2019 grant (collectively, the "RSUs").

SEC source: 0000898432-20-000615 · form4.xml · derivative · entry 2

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,268

Underlying: Common Stock · 1,268 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F2 · derivative.exercise_date: On June 26, 2019, the reporting person received restricted stock units under the Issuer's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on June 26, 2020. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F2 · derivative.expiration_date: On June 26, 2019, the reporting person received restricted stock units under the Issuer's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on June 26, 2020. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

SEC source: 0000898432-20-000615 · form4.xml · nonDerivative · entry 1

HAWKINS JAMES B · CIK 0000898243 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,815

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000898432-20-000577 · form4.xml · derivative · entry 4

McDonnell Leslie L · CIK 0001728715 · Former CEO & Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,333

Underlying: Common Stock · 94,652 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F1 · kind: As previously disclosed, the reporting person received restricted stock units under the Issuer's 2014 Equity Incentive Plan on August 19, 2019 and December 7, 2019, respectively. Pursuant to the reporting person's employment agreement with the Issuer (the "Employment Agreement"), upon her separation from the issuer without Cause (as defined in the Employment Agreement) on May 28, 2020 (the "Separation Date"), all of her unvested restricted stock units accelerated and vested on the Separation Date as follows: (i) 94,652 unvested restricted stock units accelerated and vested from the August 19, 2019 grant and (ii) 7,284 unvested restricted stock units accelerated and vested from the December 7, 2019 grant (collectively, the "RSUs").

F2 · shares: Shares surrendered to the Issuer for payment of tax liability incident to the accelerated vesting of a total of 101,936 restricted stock units.

F4 · derivative.exercise_date: All of the unvested RSUs were accelerated on the Separation Date pursuant to the terms of the Employment Agreement.

F4 · derivative.expiration_date: All of the unvested RSUs were accelerated on the Separation Date pursuant to the terms of the Employment Agreement.

SEC source: 0000898432-20-000577 · form4.xml · derivative · entry 3

McDonnell Leslie L · CIK 0001728715 · Former CEO & Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,417

Underlying: Common Stock · 7,284 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F1 · kind: As previously disclosed, the reporting person received restricted stock units under the Issuer's 2014 Equity Incentive Plan on August 19, 2019 and December 7, 2019, respectively. Pursuant to the reporting person's employment agreement with the Issuer (the "Employment Agreement"), upon her separation from the issuer without Cause (as defined in the Employment Agreement) on May 28, 2020 (the "Separation Date"), all of her unvested restricted stock units accelerated and vested on the Separation Date as follows: (i) 94,652 unvested restricted stock units accelerated and vested from the August 19, 2019 grant and (ii) 7,284 unvested restricted stock units accelerated and vested from the December 7, 2019 grant (collectively, the "RSUs").

F2 · shares: Shares surrendered to the Issuer for payment of tax liability incident to the accelerated vesting of a total of 101,936 restricted stock units.

F4 · derivative.exercise_date: All of the unvested RSUs were accelerated on the Separation Date pursuant to the terms of the Employment Agreement.

F4 · derivative.expiration_date: All of the unvested RSUs were accelerated on the Separation Date pursuant to the terms of the Employment Agreement.

SEC source: 0000898432-20-000577 · form4.xml · nonDerivative · entry 2

McDonnell Leslie L · CIK 0001728715 · Former CEO & Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 121,333

F2 · shares: Shares surrendered to the Issuer for payment of tax liability incident to the accelerated vesting of a total of 101,936 restricted stock units.

SEC source: 0000898432-20-000577 · form4.xml · nonDerivative · entry 1

McDonnell Leslie L · CIK 0001728715 · Former CEO & Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 151,936

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: As previously disclosed, the reporting person received restricted stock units under the Issuer's 2014 Equity Incentive Plan on August 19, 2019 and December 7, 2019, respectively. Pursuant to the reporting person's employment agreement with the Issuer (the "Employment Agreement"), upon her separation from the issuer without Cause (as defined in the Employment Agreement) on May 28, 2020 (the "Separation Date"), all of her unvested restricted stock units accelerated and vested on the Separation Date as follows: (i) 94,652 unvested restricted stock units accelerated and vested from the August 19, 2019 grant and (ii) 7,284 unvested restricted stock units accelerated and vested from the December 7, 2019 grant (collectively, the "RSUs").

SEC source: 0000898432-20-000499 · form4.xml · derivative · entry 6

JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,065 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F4 · derivative.exercise_date: On December 14, 2016, December 4, 2017, and December 7, 2018 the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on December 14, 2017, December 4, 2018 and December 7, 2019 respectively. The scheduled vestings were accelerated by the registrant, and the restricted stock units became vested as of April 10, 2020. Upon vesting, the reporting person received a number of shares of common stock equal to the number of restricted stock units that vested.

F4 · derivative.expiration_date: On December 14, 2016, December 4, 2017, and December 7, 2018 the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on December 14, 2017, December 4, 2018 and December 7, 2019 respectively. The scheduled vestings were accelerated by the registrant, and the restricted stock units became vested as of April 10, 2020. Upon vesting, the reporting person received a number of shares of common stock equal to the number of restricted stock units that vested.

SEC source: 0000898432-20-000499 · form4.xml · nonDerivative · entry 4

JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,663

SEC source: 0000898432-20-000499 · form4.xml · nonDerivative · entry 3

JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,005

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Restricted stock units convert into common stock on a one-for-one basis.

SEC source: 0000898432-20-000499 · form4.xml · derivative · entry 5

JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 114,474

Underlying: Common Stock · 4,000 shares

Expires 2023-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2019.

F5 · derivative.exercise_date: This option, representing a right to purchase a total of 199,759 shares, was granted on December 31, 2013 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date. 49,939 shares from this award were previously exercised in December 2015.

SEC source: 0000898432-20-000499 · form4.xml · nonDerivative · entry 2

JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,940

F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2019.

F2 · price: This transaction was executed in multiple trades at prices ranging from $20.00 to $20.57. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0000898432-20-000499 · form4.xml · nonDerivative · entry 1

JOHNSON BRENT · CIK 0001254747 · Exec. VP of WW Sales and Mktg

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,940

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2019.